These findings, in the light of the previous studies [19, 20], suggest that failure to initiate SGLT2 inhibitors in patients with AHF would be a significant missed opportunity that would prevent rehospitalization, improve quality of life, and jeopardize the opportunity to address the rising trend of hospitalization for HF in the recent years [21, 22]. This evidence concerns the gene SLC5A2 and hydrops fetalis.